Form 4: Beam Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Giuseppe Ciaramella, President of Beam Therapeutics, sold 51,110 shares of common stock on November 6, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Giuseppe Ciaramella, President of Beam Therapeutics, sold 51,110 shares of common stock on November 6, 2024.
• The sale was executed under a Rule 10b5-1 trading plan adopted on June 28, 2024.
• The shares were sold at a weighted average price of $26.3559.
• The prices for individual transactions ranged from $26.00 to $26.98.
• Following the transaction, Ciaramella directly owns 109,150 shares of Beam Therapeutics.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price within the range upon request.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan and doesn't necessarily reflect a change in the insider's view of the company.

Industry Context

Sales by company insiders are a common occurrence, and the use of a 10b5-1 trading plan allows insiders to sell shares over a period of time while avoiding concerns about insider trading. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• The sale of shares by a company president could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates